ABT
2nd
Abbott Laboratories
$194,996.90 Mn
112.69
+2.07%
-13.50%
The Established Pharmaceutical Products segment markets branded generic pharmaceuticals and biosimilars, such as Creon and Synthroid, primarily in emerging markets.
PFE
2nd
Pfizer
$155,373.10 Mn
27.26
+1.49%
+8.74%
The company operates a 'Global Hospital and Biosimilars' division and explicitly lists biosimilar products as part of its strategic portfolio and competitive advantage.
TEVJF
Teva Pharmaceutical Industries
$43,115.96 Mn
37.00
+0.00%
+158.38%
Teva is described as a biopharmaceutical company with a strong generics business, ranking among the top three global suppliers of generic prescription drugs. Its revenue is primarily driven by a broad generic portfolio including oral solids, injectables, and inhalants marketed to wholesalers and pharmacies.
BIIB
2nd
Biogen
$31,405.11 Mn
212.55
+1.63%
+56.39%
The company operates a dedicated Biosimilars segment, commercializing biosimilars of advanced biologics including BENEPALI, IMRALDI, and FLIXABI.
VTRS
Viatris
$18,572.71 Mn
16.17
-0.37%
+52.12%
Viatris is described as one of the largest providers of generic medicines globally, generating significant revenue from simple and complex generics, biosimilars, and specialty generics. The profile explicitly highlights its position as a major player in the generic drug market competing with Teva and Sandoz.
BAX
2nd
Baxter International
$13,405.71 Mn
25.93
+0.04%
+9.83%
Baxter has a dedicated Pharmaceuticals segment that generates revenue from the sale of specialty injectable pharmaceuticals and inhaled anesthetics, which fall under specialty pharmaceuticals.
CORT
2nd
Corcept Therapeutics
$12,766.42 Mn
118.10
+0.79%
+64.58%
The company generates revenue not only from its branded product but also from the sale of an authorized generic version of Korlym in the United States.
RDY
Dr Reddys Laboratories
$10,141.08 Mn
12.15
+0.25%
-14.62%
The company's Global Generics segment contributes the majority of its income through the manufacturing and marketing of generic equivalents and biosimilar alternatives to reference drugs. It is explicitly described as one of the world's leading generic pharmaceutical companies.
LQDA
2nd
Liquidia
$6,622.76 Mn
74.33
-4.34%
+168.15%
The company generates a material revenue stream through a profit-sharing arrangement with Sandoz for the promotion of a generic treprostinil injection for parenteral use.
HIMS
2nd
Hims & Hers Health
$6,392.36 Mn
27.40
-4.26%
-39.25%
The company sells and fulfills generic, brand name, and compounded medications through its own pharmacies and partner pharmacies.
BLCO
2nd
Bausch & Lomb
$6,084.25 Mn
17.04
+0.35%
+17.84%
The Pharmaceuticals segment includes a portfolio of generic ophthalmic formulations used to treat various eye conditions.
AMRX
Amneal Pharmaceuticals
$5,809.05 Mn
18.19
-1.25%
+96.44%
The company's primary revenue driver is its Affordable Medicines segment, which focuses on generic pharmaceuticals, injectables, and biosimilars, including first-to-file and first-to-market opportunities.
OGN
2nd
Organon
$3,592.49 Mn
13.68
-0.07%
+47.41%
The company has a substantial Biosimilars segment commercializing versions of reference biologics such as Hadlima and Ontruzant, as well as an Established Brands segment consisting of mature medicines that have lost patent exclusivity.
BHC
Bausch Health Companies
$2,587.40 Mn
6.92
+5.17%
-13.72%
The company describes itself as a diversified specialty pharmaceutical company with significant revenue from generic and branded generic pharmaceuticals, as well as niche specialty products in gastroenterology and neuroscience.
ANIP
Ani Pharmaceuticals
$1,837.19 Mn
76.87
+1.14%
-14.31%
ANI Pharmaceuticals focuses on specialty and generic drugs, offering over 120 generic products across various dosage forms. Its 'Generics and Other' segment specifically targets niche opportunities such as paragraph IV filings and competitive generic therapy designations.
HROW
2nd
Harrow
$1,481.38 Mn
39.52
+0.13%
+3.13%
The company operates the ImprimisRx compounding business, which provides customized formulations, alternative dosage strengths, and niche specialty pharmaceuticals to over 10,000 eye care prescribers.
ALVO
Alvotech
$1,162.48 Mn
3.95
+1.80%
-56.11%
Alvotech is focused solely on the development and manufacture of biosimilar medicines, which are specifically categorized under H-04. The company's revenue is derived from the sale of these biosimilars and licensing income from partners like Teva and STADA.
AMPH
Amphastar Pharmaceuticals
$907.64 Mn
21.34
+2.30%
-28.29%
Amphastar primarily develops, manufactures, and commercializes technically challenging generic injectable, inhalation, and intranasal products. Its revenue is driven by the sale of these generic and specialty pharmaceuticals to hospitals, clinics, and pharmacies.
FENC
Fennec Pharmaceuticals
$415.85 Mn
11.87
+0.34%
+44.76%
Fennec is described as a specialty pharmaceutical company focusing on a niche indication (cisplatin-induced ototoxicity). It generates revenue from the sale of its specialty therapy, PEDMARK, and through licensing and distribution agreements for the same product.
SLGL
2nd
Sol-Gel Technologies
$225.05 Mn
79.33
-4.43%
+392.73%
The company has a dedicated Generic Drug Development segment, which includes a collaboration with Padagis to develop a generic version of Zoryve Cream in exchange for quarterly fees and royalties.
DERM
2nd
Journey Medical
$183.11 Mn
6.66
+3.10%
-4.86%
The company's portfolio includes Accutane, which is a well-known specialty/generic pharmaceutical in the dermatology space, and it operates in a market alongside specialty pharmaceutical players.
NRXP
2nd
NRX Pharmaceuticals
$115.14 Mn
3.44
+0.29%
+24.64%
The company is developing KETAFREE, which is explicitly described as a generic ketamine product intended for the existing anesthetic market.
NTRB
NutriBand
$41.94 Mn
3.45
+6.81%
-45.75%
Nutriband focuses on developing abuse-deterrent versions of existing generic drugs, such as AVERSA Fentanyl, AVERSA Buprenorphine, and AVERSA Methylphenidate. These products utilize the 505(b)(2) regulatory pathway to create specialty pharmaceuticals based on approved generic ingredients.
BGM
Bgm
$32.85 Mn
0.29
+7.41%
-96.44%
The company manufactures and sells oxytetracycline tablets, licorice products, and heparin, which are specialty and generic pharmaceutical products. It sells these to a large network of distributors and dealers across China.
ETST
Earth Science Tech
$25.88 Mn
0.09
+0.00%
-55.00%
The company generates primary revenue from the sale of compounded medications through its RxCompound and Mister Meds pharmacies, which are licensed compounding pharmacies.
AYTU
2nd
Aytu Biopharma
$25.33 Mn
2.36
+0.00%
+7.27%
The company maintains a Pediatric Portfolio consisting of legacy prescription pediatric products acquired from Cerecor, Inc., which fits the description of specialty pharmaceuticals.
GRML
Greenland Mines
$24.04 Mn
0.19
-5.00%
-75.84%
The company generates its primary current revenue from the sale of 5 market-approved generic anti-cancer drugs in Germany and 2 off-patent biosimilar antibodies marketed as cost-effective alternatives to branded biologics.
NXPL
NextPlat
$21.81 Mn
8.07
-4.61%
+10.55%
The company's primary revenue driver (73%) comes from its Healthcare Operations, specifically through Pharmco, which dispenses prescription pharmaceuticals, compounded medications, and specialty medications. This aligns with the Generic Drugs industry, which covers specialty pharmaceuticals and niche formulation-specialized medicines.
RDHL
RedHill Biopharma
$20.96 Mn
0.59
+1.72%
-59.03%
RedHill Biopharma is described as a specialty biopharmaceutical company that commercializes Talicia®, a rifabutin-based triple regimen for H. pylori. The profile explicitly identifies it as a 'specialty biopharmaceutical company' and notes that Talicia® competes with both branded therapies and generic versions, fitting the H-04 classification for specialty pharmaceuticals.
SCNX
Scienture Holdings
$18.89 Mn
0.46
-2.13%
-61.02%
Scienture LLC operates as a specialty pharmaceutical company focusing on niche formulations and biosimilars, such as Arbli (an oral liquid formulation of losartan) and a biosimilar candidate targeting Cathflo Activase. Its business model centers on specialty pharmaceuticals and the 351(k) pathway for biosimilars, which aligns with the H-04 classification for specialty and biosimilar drugs.
HIND
2nd
Vyome Holdings
$15.93 Mn
2.27
+0.00%
-74.00%
The company has a pharmaceutical segment that commercializes specialty antifungal products, such as Luliconazole cream and dandruff treatments, through a licensing and royalty agreement with Sun Pharma Laboratories Limited.
AEON
AEON Biopharma
$12.63 Mn
0.25
-3.85%
-66.67%
AEON Biopharma is specifically developing a botulinum toxin product candidate as a biosimilar to Botox. The company intends to follow the 351(k) biosimilar pathway to secure regulatory approval for therapeutic indications.
COSM
Cosmos Health
$8.62 Mn
0.21
+5.00%
-75.29%
The company's primary business includes the development, manufacture, and sale of generic pharmaceutical products such as ASTO-CHOL, Diorium, and LIPICHOL. It operates a dedicated 'Generic Medicines' segment and serves retail pharmacies, hospitals, and wholesalers.
MGRX
2nd
Mangoceuticals
$8.47 Mn
0.47
-11.32%
-69.97%
The company generates primary revenue from the sale of compounded pharmaceutical products for erectile dysfunction, hair loss, and hormone balance, which fall under specialty pharmaceuticals.
PMHS
Polomar Health Services
$8.42 Mn
0.30
+114.29%
+50.00%
Polomar operates a licensed retail compounding pharmacy that prepares sterile and non-sterile custom medications, which falls under specialty pharmaceuticals. Revenue is primarily generated from the sale of these compounded prescription medications.
SXTP
60 Degrees Pharmaceuticals
$1.93 Mn
1.12
+3.70%
-78.46%
The company describes itself as a 'specialty pharmaceutical company' and focuses on niche markets with high unmet needs, such as malaria prophylaxis and babesiosis. Its revenue is primarily derived from the sale of Arakoda, a specialty pharmaceutical product marketed for malaria prevention.
SBFM
Sunshine Biopharma
$1.53 Mn
1.12
+0.00%
-92.38%
The company's primary revenue driver is the sale of 71 generic prescription drugs through its subsidiary Nora Pharma Inc, covering therapeutic areas such as oncology and cardiovascular health.
PRFX
PRF Technologies
$0.61 Mn
0.94
-3.09%
-85.97%
The company focuses on reformulating generic drugs to create extended release product candidates, specifically citing PRF 110 (ropivacaine) and OcuRing™ K (ketorolac). Its business model is centered on the 505(b)(2) pathway for specialty pharmaceuticals.
QNRX
Quoin Pharmaceuticals
$0.47 Mn
4.97
-3.87%
-30.49%
Quoin Pharmaceuticals is described as a 'specialty pharmaceutical company' focusing on rare and orphan diseases. Its lead candidate QRX003 and other pipeline products like QRX008 and QRX009 are targeted at niche, orphan indications such as Netherton Syndrome and scleroderma, which aligns with the 'specialty pharmaceuticals' definition in H-04.
FCHS
2nd
First Choice Healthcare Solutions
$0.33 Mn
0.01
+0.00%
+0.00%
The company operates Live Well Drugstore, Inc., a compounding pharmacy that prepares and sells customized medications for hormone optimization, anti-aging, and weight loss.